Events & Presentations
Board of Directors
Historic Stock Lookup
Peter G. Traber, M.D., CEO and CMO of Galectin Therapeutics, to Speak on the Medical Applications of Plant-Derived Complex Carbohydrates
July 13, 2016 | Press Release
Galectin Therapeutics Receives Notice of Australian Patent to be Granted for the Use of GR-MD-02 in Liver, Kidney, Lung or Heart Fibrosis
July 12, 2016 | Press Release
Galectin Therapeutics Announces Positive Preclinical Results on the Role of Galectin-3 in Mediating Vascular Remodeling in Pulmonary Arterial Hypertension
June 2, 2016 | Press Release
What are galectins and why are they a good target for the treatment of NASH?
Are you conducting clinical trials with GR-MD-02? What results have you seen so far?
Why did you choose to become the CEO of Galectin Therapeutics?
Why is fatty liver disease called "the hidden epidemic?"
What is fibrosis and what role does it play in chronic diseases such as NASH?
Galectin Therapeutics, Inc.
Financial Tear Sheet
Filings & Reports
Stock price updates every 30 minutes.
2015 Year In Review
Latest Corporate Presentation
Media Fact Sheet
Corporate Fact Sheet
Sign up for our latest updates
© 2016 Galectin Therapeutics Inc. - All Rights Reserved
Disclaimer: This site may contain